Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe

OBJECTIVES: The efficacy and safety of certolizumab pegol (CZP), an Fc-free, PEGylated anti-TNF, in axial spondyloarthritis (axSpA) has been established in clinical trial settings. We report CZP effectiveness and safety in European clinical practice in patients with axSpA, including radiographic (r-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Rheumatology (Oxford)
Autors principals: Baraliakos, Xenofon, Witte, Torsten, De Clerck, Luc, Frediani, Bruno, Collantes-Estévez, Eduardo, Katsifis, Gkikas, VanLunen, Brenda, Kleine, Elisabeth, Hoepken, Bengt, Bauer, Lars, Goodson, Nicola
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Science
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7785316/
https://ncbi.nlm.nih.gov/pubmed/32584415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/keaa181
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars